Abstract
Domiciliary oxygen therapy is often prescribed for patients with hypoxaemia due to advanced lung disease, most commonly chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). Long-term oxygen therapy (LTOT) trials conducted in patients with COPD in the 1980s remain the basis for clinical decisions and guideline recommendations regarding LTOT for patients with non-COPD conditions as there is a lack of high-quality evidence concerning its use in the non-COPD population. There is also a lack of evidence for the use of ambulatory and nocturnal oxygen therapy in patients with isolated exertional and nocturnal hypoxaemia. These deficiencies pose significant challenges in patient care, with consequent discrepancies in guideline recommendations and clinical approaches. In recent years, new studies have been and are currently being conducted to fill the gaps in our understanding and use of domiciliary oxygen therapy for other indications, including ILD. This article provides a comparison of the epidemiology and significance of hypoxaemia in patients with COPD and ILD, with an up-to-date review of current evidence regarding the role of different types of domiciliary oxygen therapy in these conditions.
Abstract
Despite the significance of hypoxaemia in patients with chronic lung diseases, an up-to-date review shows current evidence for clinical use of domiciliary oxygen therapy remains limited http://bit.ly/33aW31n
Footnotes
Conflict of interest: Y.H. Khor reports grants from Boehringer Ingelheim, personal fees from Boehringer Ingelheim and Roche, and in-kind support for a clinical trial from Air Liquide Healthcare, outside the submitted work.
Conflict of interest: E.A. Renzoni reports lecture fees and advisory board fees from Boehringer Ingelheim and from Roche, lecture fees from Mundipharma, outside the submitted work.
Conflict of interest: D. Visca has nothing to disclose.
Conflict of interest: C.F. McDonald reports grants from Boehringer Ingelheim, in-kind support for a clinical trial from Air Liquide Healthcare, and speaker's fees paid to her hospital by Menarini and AstraZeneca, outside the submitted work.
Conflict of interest: N.S.L. Goh reports personal fees from Roche and AstraZeneca, grants and personal fees from Boehringer Ingelheim, and in-kind support for a clinical trial from Air Liquide Healthcare, outside the submitted work.
- Received May 14, 2019.
- Accepted July 29, 2019.
- Copyright ©ERS 2019
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.